Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 1/20 | 0.57 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.46 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.44 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.43 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2822843 | 1.00 | LTA4H (0.57) | LTA4HP2RX7CHRNB2CHRNA4MAPT | |
| SCHEMBL1367956 | 1.00 | LTA4H (0.57) | LTA4HP2RX7CHRNB2CHRNA4MAPT | |
| SCHEMBL643358 | 1.00 | LTA4H (0.57) | LTA4HP2RX7CHRNB2CHRNA4MAPT | |
| Iodide SCHEMBL8989630 | 0.98 | LTA4H (0.56) | LTA4HP2RX7CHRNB2CHRNA4MAPT | |
| Hydrochloric Acid SCHEMBL1367998 | 0.98 | LTA4H (0.56) | LTA4HP2RX7CHRNB2CHRNA4MAPT | |
| Bromide SCHEMBL5857053 | 0.98 | LTA4H (0.56) | LTA4HP2RX7CHRNB2CHRNA4MAPT | |
| Bromide SCHEMBL939381 | 0.98 | LTA4H (0.56) | LTA4HP2RX7CHRNB2CHRNA4MAPT | |
| Bromide SCHEMBL1363188 | 0.98 | LTA4H (0.56) | LTA4HP2RX7CHRNB2CHRNA4MAPT | |
| Hydrochloric Acid SCHEMBL18111693 | 0.98 | LTA4H (0.56) | LTA4HP2RX7CHRNB2CHRNA4MAPT | |
| SCHEMBL17472381 | 0.87 | CHRM3 (0.55) | LTA4HP2RX7CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10399933-B2 | Inhibitors of indoleamine-2,3-dioxygenase for the treatment of cancer | BRISTOL-MYERS SQUIBB COMPANY (US) | 2019-09-03 | — | — | US | disclosed |
| US-10399932-B2 | Inhibitors of indoleamine-2,3-dioxygenase for the treatment of cancer | BRISTOL-MYERS SQUIBB COMPANY (US) | 2019-09-03 | — | — | US | disclosed |
| US-10167254-B2 | IDO inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2019-01-01 | — | — | US | disclosed |
| US-20180079712-A1 | INHIBITORS OF INDOLEAMINE-2,3-DIOXYGENASE FOR THE TREATMENT OF CANCER | BRISTOL MYERS SQUIBB CO (US) | 2018-03-22 | — | — | US | disclosed |
| US-20180072660-A1 | INHIBITORS OF INDOLEAMINE-2,3-DIOXYGENASE FOR THE TREATMENT OF CANCER | BRISTOL MYERS SQUIBB CO (US) | 2018-03-15 | — | — | US | disclosed |
| US-9790169-B2 | IDO inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-10-17 | — | — | US | disclosed |
| US-20170231999-A1 | IDO INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2017-08-17 | — | — | US | disclosed |
| US-20160289171-A1 | IDO INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2016-10-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10167254-B2 | IDO inhibitors | IDO1, IDO2, INMT | LTA4H 646/4885P2RX7 2411/4885CHRNB2 4359/4885 |
| US-20170231999-A1 | IDO INHIBITORS | IDO1, IDO2, INMT | LTA4H 646/4885P2RX7 2411/4885CHRNB2 4359/4885 |
| US-10399932-B2 | Inhibitors of indoleamine-2,3-dioxygenase for the treatment of cancer | IDO1, IDO2, INMT | LTA4H 692/4885P2RX7 2716/4885CHRNB2 3434/4885 |
| US-20180072660-A1 | INHIBITORS OF INDOLEAMINE-2,3-DIOXYGENASE FOR THE TREATMENT OF CANCER | IDO1, IDO2, INMT | LTA4H 692/4885P2RX7 2716/4885CHRNB2 3434/4885 |
| US-10399933-B2 | Inhibitors of indoleamine-2,3-dioxygenase for the treatment of cancer | IDO1, IDO2, INMT | LTA4H 692/4885P2RX7 2716/4885CHRNB2 3434/4885 |
| US-20160289171-A1 | IDO INHIBITORS | IDO1, IDO2, INMT | LTA4H 646/4885P2RX7 2411/4885CHRNB2 4359/4885 |
| US-20180079712-A1 | INHIBITORS OF INDOLEAMINE-2,3-DIOXYGENASE FOR THE TREATMENT OF CANCER | IDO1, IDO2, INMT | LTA4H 692/4885P2RX7 2716/4885CHRNB2 3434/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.